Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health, Flatiron Health Partner to Link ctDNA Results, Clinical Records

NEW YORK (GenomeWeb) – Guardant Health and Flatiron Health have announced a collaboration to integrate Guardant Health's liquid biopsy genomic testing results with clinical treatment and outcomes data using Flatiron's cloud-based information platform. 

The partners said this new ability to link patients' genomic data with their clinical records will hopefully support the accelerated development of targeted therapies for cancer by enabling life science companies to more quickly recruit and select patients for trials and to more easily follow subjects and their progress over time.

Under the new agreement, Guardant Health and Flatiron Health will work together to develop products that integrate patients' de-identified clinical treatment and outcomes data — using Flatiron's OncologyCloud electronic medical record, analytics, and patient portal platform — with genomic data for patients who have undergone testing with Guardant360, Guardant's circulating tumor DNA test.

The new information platform will be available to interested life science companies in the first half of 2016, in compliance with the Health Insurance Portability and Accountability Act, the companies said.